TOCILIZUMAB
tocilizumab 400 mg/20 mL injection, 20 mL vial
TOCILIZUMAB (12810F)
12810F
Manner of administration:Injection
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilizumab after resolution of the critical shortage of tocilizumab)
Restriction
Indication: Severe active juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 4 (Temporary listing - change of treatment from another
biological medicine to tocilzumab after resolution of the critical shortage of tocilizumab)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $424.25 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Actemra | |||||